Wall Street brokerages expect that NightHawk Biosciences (NYSE:NHWK – Get Rating) will report earnings per share of ($0.38) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for NightHawk Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.42) and the highest estimate coming in at ($0.33). NightHawk Biosciences posted earnings per share of ($0.26) in the same quarter last year, which suggests a negative year over year growth rate of 46.2%. The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that NightHawk Biosciences will report full year earnings of ($1.48) per share for the current year, with EPS estimates ranging from ($1.73) to ($1.29). For the next year, analysts expect that the business will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.32) to ($1.23). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow NightHawk Biosciences.
NightHawk Biosciences (NYSE:NHWK – Get Rating) last released its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.09. NightHawk Biosciences had a negative net margin of 1,995.52% and a negative return on equity of 30.28%.
NightHawk Biosciences stock opened at $2.53 on Friday. The firm has a 50-day moving average price of $2.51 and a 200-day moving average price of $2.96. The firm has a market capitalization of $64.89 million, a PE ratio of -1.78 and a beta of 0.45. NightHawk Biosciences has a 12-month low of $1.60 and a 12-month high of $10.85.
A number of hedge funds have recently bought and sold shares of NHWK. Wolverine Trading LLC purchased a new position in NightHawk Biosciences in the 4th quarter worth about $33,000. Walleye Trading LLC purchased a new position in NightHawk Biosciences during the 4th quarter valued at about $55,000. Walleye Capital LLC purchased a new position in NightHawk Biosciences during the 4th quarter valued at about $76,000. Cubist Systematic Strategies LLC purchased a new position in NightHawk Biosciences during the 4th quarter valued at about $82,000. Finally, Goldman Sachs Group Inc. increased its position in NightHawk Biosciences by 12.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 56,465 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 6,278 shares during the period. 18.12% of the stock is currently owned by institutional investors.
NightHawk Biosciences Company Profile (Get Rating)
Heat Biologics, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.
- Get a free copy of the StockNews.com research report on NightHawk Biosciences (NHWK)
- MarketBeat: Week in Review 5/30 – 6/3
- Dividend Capture Strategy: What You Need to Know
- Okta On Verge Of Multi-Week Rally
- Xiaomi Co: Facing Macro Headwinds
- Don’t Bet On A Bounce For RH
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NightHawk Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NightHawk Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.